OUTCOMES OF TREATMENT OF CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH CENTRAL SEROUS CHORIORETINOPATHY WITH INTRAVITREAL ANTIANGIOGENIC AGENTS.

Abstract

PURPOSE:

To report clinical characteristics and treatment outcomes from the largest case series of choroidal neovascularization secondary to central serous chorioretinopathy.

METHODS:

Retrospective analysis of 46 eyes of 43 consecutive subjects. Collected data included demographic details, history of presenting illness, clinical examination details including visual acuity at presentation and follow-up with imaging and treatment details. Main outcome measures were the proportion of eyes that had improved (3 or more lines), stable (within ±1 line), or decreased (3 or more lines) vision at the final visit as compared with baseline examination. Secondary efficacy outcomes included change in visual acuity at final follow-up, number of injections, treatment-free interval, and adverse events.

RESULTS:

Mean age was 57.56 years (range 29-79 years). Mean follow-up duration was 38.3 months ± 58.9 months. More than 3 lines of improvement in 12 eyes (26%), vision was stable (within ±1 line) in 19 eyes (41.3%), and >3 lines of loss was noted in 6 eyes (13%). Mean change in the number of lines was 1.16 ± 3.74. Mean number of anti-vascular endothelial growth factor injections during the follow-up was 4.45 ± 4.1. The longest treatment-free interval was 8.9 months ± 7.5 months. There were no adverse events noted.

CONCLUSION:

Anti-vascular endothelial growth factor therapy as a primary therapy for choroidal neovascularization secondary to central serous chorioretinopathy is safe and efficacious, without any serious adverse events.

• Authors: Jay Chhablani, Igor Kozak, Francesco Pichi, Megan Chenworth, Maria H Berrocal, Rumneek Bedi, Rishi P Singh, Lihteh Wu, Catherine Meyerle, Antonio Marcelo Casella, Ahmad Mansour, Ziad Bashshur, Antonella Scorza, Paola Carrai, Paolo Nucci, J Fernando Arevalo, King Khaled Eye Specialist Hospital International Collaborative Retina Study Group
• Journal: Retina (Philadelphia, Pa.) (Retina) Vol. 35 Issue 12 Pg. 2489-97 (Dec 2015) ISSN: 1539-2864 [Electronic] United States
• PMID: 26110597 (Publication Type: Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Vascular Endothelial Growth Factor A
• Bevacizumab
• Ranibizumab

Topics

• Adult
• Aged
• Angiogenesis Inhibitors (administration & dosage)
• Antibodies, Monoclonal, Humanized (administration & dosage)
• Bevacizumab (administration & dosage)
• Central Serous Chorioretinopathy (complications, drug therapy)
• Choroidal Neovascularization (drug therapy, etiology)
• Female
• Humans
• Intravitreal Injections
• Male
• Middle Aged
• Ranibizumab (administration & dosage)
• Retrospective Studies
• Tomography, Optical Coherence
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity